Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company specializing in virology, has recently announced a significant development in its ongoing patent infringement lawsuit against Moderna, Inc. In collaboration with its licensee Genevant Sciences, Arbutus seeks damages for the alleged infringement of several U.S. patents in the manufacture and sale of Moderna’s COVID-19 vaccine, MRNA-1273. The U.S. District Court for the District of Delaware has issued a claim construction ruling, which will have significant implications for the future of this lawsuit.
Background:Arbutus Biopharma is committed to developing a functional cure for individuals with chronic hepatitis B virus (cHBV) infection. As part of its research efforts, the company holds several crucial U.S. patents, namely 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378. These patents are aimed at protecting Arbutus’s intellectual property rights and innovations in the virology field.
Lawsuit Details:Arbutus and Genevant Sciences initiated the patent infringement lawsuit against Moderna and its affiliate for allegedly using their patented technology in the manufacturing and distribution of MRNA-1273, Moderna’s prominent COVID-19 vaccine. The claim construction ruling by the U.S. District Court for the District of Delaware will play a pivotal role in determining the interpretation and scope of the disputed patent claims in question.
Significance of Claim Construction Ruling:The claim construction ruling serves as an essential milestone in the ongoing lawsuit and will considerably impact the potential outcome and damages sought by Arbutus and Genevant Sciences. It will define the meaning and boundaries of the patent claims being asserted and shape how the case progresses further.
Implications for Arbutus and Genevant Sciences:Depending on the court’s interpretation of the patent claims, the claim construction ruling may strengthen their case against Moderna and their affiliate. It will enable them to solidify their argument regarding the alleged infringement of their patents by MRNA-1273. The ruling will support their pursuit of adequate compensation and protect their intellectual property rights. Arbutus and Genevant Sciences remain confident that the court will recognize the validity and merits of their claims.
Conclusion:The claim construction ruling in Arbutus Biopharma and Genevant Sciences’ patent infringement lawsuit against Moderna represents a significant development in their ongoing legal battle. As the U.S. District Court for the District of Delaware determines the interpretation and scope of the patent claims, the ruling will have far-reaching implications for the case’s outcome. Both Arbutus and Genevant Sciences remain committed to protecting their intellectual property rights and seeking appropriate compensation for the alleged infringement by Moderna’s COVID-19 vaccine, MRNA-1273.
Comments